Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD19 CAR T-cells in Relapsed/Refractory Aggressive Lymphoma or ALL
NCT03938987Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- Mar 2021
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), sponsored by University of Alberta. Primary endpoints: Treatment-related adverse events at 3 years, Dose limiting toxicities at 3 years and 4 more. Started Mar 2021; status: recruiting.
02
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03938987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938987.